Azadirachtin B is an limonoid isolated from seed kernels of Azadirachta indica and it is active against the Epstein-Barr virus early antigen (EBV-EA). Azadirachtin B increases alkaline phosphatase (ALP) activity and stimulates osteoblast differentiation. Azadirachtin B has insecticidal, nematocidal, anticancer, anti-inflammatory, antiviral and osteogenic properties[1][2][3].

Azadirachtin B increases expression of RunX-2 ～2.5 fold at 10 nM concentration, ALP expression ～2.8 fold at 10 nM and 100 pM concentration and OCN expression ～2.5 folds at 10 nM as compared with control[1]. Azadirachtin B (1 pM-100 μM; 48 hours; Osteoblast cells) treatment shows highest proliferation at 10 nM and 100 pM concentrations in osteoblast cells[1]. Azadirachtin B (compound 21) exhibits moderate or potent inhibitory effects (IC50 value of 384 mol ratio/32 pmol TPA) against the Epstein-Barr virus early antigen (EBV-EA) activation induced by tetradecanoylphorbol-13-acetate (TPA)[3]. Azadirachtin B (Compound 4) exhibits toxicity to the diamondback moth (Plutella xylostella) with an LD50 of 4.85-1.06 μg/g body weight, in 92 h[2].

On evaluation of Azadirachtin B (compound 21; oral administration) for its anti-tumor-initiating activity on the two-stage carcinogenesis of mouse skin tumor induced by peroxynitrite (ONOO-; PN) as an initiator and TPA as a promoter, this exhibited marked inhibitory activity[3].

106500-25-8

C33H42O14

662.68

Azadirachtin B

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years